The heterogeneity of tumour immune microenvironment revealing the CRABP2/CD69 signature discriminates distinct clinical outcomes in breast cancer.
Mei J, Cai Y, Chen L, Wu Y, Liu J, Qian Z, Jiang Y, Zhang P, Xia T, Pan X, et al. Br J Cancer. 2023 Nov; 129(10):1645-1657. Epub 2023 Sep 15.